Table 1.
Association between PKM2 expression and clinicopathological features of 173 LUAD patients
| Characteristic | No. of patients (%) | PKM2 expression | P-value | |
|---|---|---|---|---|
| Low | High | |||
| Age (years), median (range) | 47 (27–67) | |||
| ≤ 60 | 149 (86.1%) | 77 (51.7%) | 72 (48.3%) | 0.080 |
| > 60 | 24 (13.9%) | 17 (70.8%) | 7 (29.2%) | |
| Sex | ||||
| Male | 124 (71.7%) | 67 (54.0%) | 57 (46.0%) | 0.899 |
| Female | 49 (28.3%) | 27 (55.1%) | 22 (44.9%) | |
| Smoking history | ||||
| Never | 118 (68.2%) | 64 (54.2%) | 54 (45.8%) | 0.970 |
| Current/Former | 55 (31.8%) | 30 (54.5%) | 25 (45.5%) | |
| pT classification | ||||
| T1 | 48 (27.7%) | 33 (68.8%) | 15 (31.3%) | 0.114 |
| T2 | 67 (38.7%) | 31 (46.3%) | 36 (53.7%) | |
| T3 | 46 (26.6%) | 24 (52.2%) | 22 (47.8%) | |
| T4 | 12 (6.9%) | 6 (50.0%) | 6 (50.0%) | |
| pN classification | ||||
| N0 | 100 (57.8%) | 62 (62.0%) | 38 (38.0%) | 0.006 |
| N1 | 47 (27.2%) | 25 (53.2%) | 22 (46.8%) | |
| N2–3 | 26 (15.0%) | 7 (26.9%) | 19 (73.1%) | |
| pM classification | ||||
| M0 | 160 (92.5%) | 89 (55.6%) | 71 (44.4%) | 0.232 |
| M1 | 13 (7.5%) | 5 (38.5%) | 8 (61.5%) | |
| pTNM stage | ||||
| I | 51 (29.5%) | 38 (74.5%) | 13 (25.5%) | 0.005 |
| II | 66 (38.2%) | 33 (50.0%) | 33 (50.0%) | |
| III | 43 (24.9%) | 18 (41.9%) | 25 (58.1%) | |
| IV | 13 (7.5%) | 5 (38.5%) | 8 (61.5%) | |
| Positive EGFR mutational status | 20 (11.6%) | 12 (12.8%) | 8 (10.1%) | |
| Positive KRAS mutational status | 25 (14.4%) | 14 (14.9%) | 11 (13.9%) | |
| Positive ALK translocation status | 8 (4.6%) | 5 (5.3%) | 3 (3.8%) | |
PKM2, pyruvate kinase M2; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homologue; ALK, anaplastic lymphoma kinase; LUAD, lung adenocarcinoma